A Comparison of Acute and Chronic Toxicity for Men With Low-Risk Prostate Cancer Treated With Intensity-Modulated Radiation Therapy or 125I Permanent Implant

International Journal of Radiation Oncology Biology Physics

Volumn 71, Issue 2, 2008, Pages 338-345

  Eade, Thomas N ^a   Horwitz, Eric M ^a   Ruth, Karen ^a   Buyyounouski, Mark K ^a   D'Ambrosio, David J ^a   Feigenberg, Steven J ^a   Chen, David Y T ^a   Pollack, Alan ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Brachytherapy; IMRT; Prostate cancer; Radiation therapy; Toxicity

Indexed keywords

BIOCHEMISTRY; DRUG THERAPY; RADIOTHERAPY; TOXICITY;

BRACHYTHERAPY; INTENSITY-MODULATED RADIATION THERAPY (IMRT); PROSTATE CANCER;

ONCOLOGY;

IODINE 125;

ADOLESCENT; ADULT; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER RISK; CONTROLLED STUDY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; UROGENITAL TRACT DISEASE;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; CHRONIC DISEASE; FOLLOW-UP STUDIES; GASTROINTESTINAL TRACT; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY, INTENSITY-MODULATED; UROGENITAL SYSTEM;

EID: 43049160704     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.10.019     Document Type: Article

References (32)

1. Potters L., Morgenstern C., Calugaru E., et al. 12-Year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 173 (2005) 1562-1566
2. Kupelian P., Kuban D., Thames H., et al. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: The combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys 61 (2005) 415-419
3. Potters L., Klein E.A., Kattan M.W., et al. Monotherapy for stage T1-T2 prostate cancer: Radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol 71 (2004) 29-33
4. D'Amico A., Whittington R., Malkowicz S., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
5. Kupelian P.A., Potters L., Khuntia D., et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004) 25-33
6. Hanks G.E., Hanlon A.L., Epstein B., et al. Dose response in prostate cancer with 8-12 years' follow-up. Int J Radiat Oncol Biol Phys 54 (2002) 427-435
7. Davis J.W., Kuban D.A., Lynch D.F., et al. Quality of life after treatment for localized prostate cancer: Differences based on treatment modality. J Urol 166 (2001) 947-952
8. Zelefsky M.J., Fuks Z., Hunt M., et al. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53 (2002) 1111-1116
9. Kupelian P.A., Reddy C.A., Klein E.A., et al. Short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Preliminary results on late toxicity and quality of life. Int J Radiat Oncol Biol Phys 51 (2001) 988-993
10. Zelefsky M.J., Chan H., Hunt M., et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176 (2006) 1415-1419
11. Pollack A., Hanlon A.L., Horwitz E.M., et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 64 (2006) 518-526
12. Parker C.C., Damyanovich A., Haycocks T., et al. Magnetic resonance imaging in the radiation treatment planning of localized prostate cancer using intra-prostatic fiducial markers for computed tomography co-registration. Radiother Oncol 66 (2003) 217-224
13. American Joint Committee on Cancer. Prostate. In: Greene F.L., Page D.L., Fleming I.D., et al. (Eds). AJCC Cancer Staging Manual (2002), Springer, New York 337-345
14. Nath R., Anderson L.L., Luxton G., et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine. Med Phys 22 (1995) 209-234
15. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
16. Hanlon A.L., Schultheiss T.E., Hunt M.A., et al. Chronic rectal bleeding after high-dose conformal treatment of prostate cancer warrants modification of existing morbidity scales. Int J Radiat Oncol Biol Phys 38 (1997) 59-63
17. Storey M.R., Pollack A., Zagars G., et al. Complications from radiotherapy dose escalation in prostate cancer: Preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 48 (2000) 635-642
18. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 447-457
19. Cox D.R., and Oakes D. Analysis of Survival Data (1984), Chapman & Hall, London
20. Zelefsky M., Wallner L., Ling C., et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol 17 (1999) 517-522
21. Merrick G.S., Butler W.M., Wallner K.E., et al. Long-term urinary quality of life after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 56 (2003) 454-461
22. Lee W.R., Hall M.C., McQuellon R.P., et al. A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy. Int J Radiat Oncol Biol Phys 51 (2001) 614-623
23. Feigenberg S.J., Lee W.R., Desilvio M.L., et al. Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. Int J Radiat Oncol Biol Phys 62 (2005) 956-964
24. Merrick G.S., Butler W.M., Wallner K.E., et al. Rectal function following brachytherapy with or without supplemental external beam radiation: Results of two prospective randomized trials. Brachytherapy 2 (2003) 147-157
25. Zelefsky M.J., Yamada Y., Cohen G.N., et al. Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 67 (2007) 65-70
26. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
27. Peeters S.T., Heemsbergen W.D., van Putten W.L., et al. Acute and late complications after radiotherapy for prostate cancer: Results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 61 (2005) 1019-1034
28. Tucker S.L., Zhang M., Dong L., et al. Cluster model analysis of late rectal bleeding after IMRT of prostate cancer: A case-control study. Int J Radiat Oncol Biol Phys 64 (2006) 1255-1264
29. Huang E.H., Pollack A., Levy L., et al. Late rectal toxicity: Dose-volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 54 (2002) 1314-1321
30. Taussky D., Yeung I., Williams T., et al. Rectal-wall dose dependence on postplan timing after permanent-seed prostate brachytherapy. Int J Radiat Oncol Biol Phys 65 (2006) 358-363
31. Buyyounouski M.K., Hanlon A.L., Eisenberg D.F., et al. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer. Int J Radiat Oncol Biol Phys 63 (2005) 1455-1462
32. Pickles T. Prostate-specific antigen (PSA) bounce and other fluctuations: Which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy. Int J Radiat Oncol Biol Phys 64 (2006) 1355-1359